Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$52.01
+0.3%
$48.88
$21.02
$58.40
$4.13B-0.151.05 million shs404,821 shs
Merus N.V. stock logo
MRUS
Merus
$53.84
+1.0%
$49.89
$33.19
$62.98
$3.73B1738,077 shs222,443 shs
Oculis Holding AG stock logo
OCS
Oculis
$18.96
-1.1%
$18.89
$10.79
$23.08
$829.59M0.2945,369 shs8,545 shs
Organon & Co. stock logo
OGN
Organon & Co.
$10.08
-0.7%
$9.61
$8.01
$23.10
$2.59B0.63.54 million shs2.38 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
+0.26%-7.58%+0.78%+41.61%+137.18%
Merus N.V. stock logo
MRUS
Merus
+0.96%+1.24%-13.75%+41.28%+1.68%
Oculis Holding AG stock logo
OCS
Oculis
-1.07%-2.70%-2.49%+22.29%+62.01%
Organon & Co. stock logo
OGN
Organon & Co.
-0.84%+0.88%+6.78%-22.71%-50.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.5687 of 5 stars
3.51.00.04.71.80.80.0
Merus N.V. stock logo
MRUS
Merus
1.8669 of 5 stars
3.61.00.00.01.42.50.0
Oculis Holding AG stock logo
OCS
Oculis
1.7686 of 5 stars
3.53.00.00.00.60.00.6
Organon & Co. stock logo
OGN
Organon & Co.
4.8251 of 5 stars
3.34.01.73.71.73.31.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$82.5058.61% Upside
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6457.20% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$35.3386.41% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.50
Moderate Buy$18.0078.66% Upside

Current Analyst Ratings Breakdown

Latest OCS, AKRO, MRUS, and OGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$63.00 ➝ $64.00
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/22/2025
Organon & Co. stock logo
OGN
Organon & Co.
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/19/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/15/2025
Organon & Co. stock logo
OGN
Organon & Co.
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.00
5/13/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $78.00
5/9/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $33.00
5/8/2025
Merus N.V. stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/5/2025
Organon & Co. stock logo
OGN
Organon & Co.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.00
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Inline
4/28/2025
Merus N.V. stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Merus N.V. stock logo
MRUS
Merus
$36.13M103.13N/AN/A$9.46 per share5.69
Oculis Holding AG stock logo
OCS
Oculis
$780K1,060.99N/AN/A$1.91 per share9.92
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.41$4.99 per share2.02$1.83 per share5.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.883.502.691.0411.92%227.43%7.34%8/5/2025 (Estimated)

Latest OCS, AKRO, MRUS, and OGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/12/2025Q1 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$1.01$0.90+$1.91$0.90N/AN/A
5/8/2025Q1 2025
Oculis Holding AG stock logo
OCS
Oculis
-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million
5/1/2025Q1 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.79%N/A2.78%N/A

Latest OCS, AKRO, MRUS, and OGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.8%5/12/20255/12/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.03
16.80
16.80
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86
Oculis Holding AG stock logo
OCS
Oculis
N/A
4.79
4.79
Organon & Co. stock logo
OGN
Organon & Co.
16.49
1.67
1.15

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Merus N.V. stock logo
MRUS
Merus
96.14%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Merus N.V. stock logo
MRUS
Merus
4.57%
Oculis Holding AG stock logo
OCS
Oculis
N/A
Organon & Co. stock logo
OGN
Organon & Co.
1.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.72 million74.08 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.96 million254.86 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$52.01 +0.13 (+0.26%)
Closing price 07/3/2025 02:56 PM Eastern
Extended Trading
$52.06 +0.04 (+0.08%)
As of 07/3/2025 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Merus stock logo

Merus NASDAQ:MRUS

$53.84 +0.51 (+0.96%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$53.38 -0.46 (-0.85%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Oculis stock logo

Oculis NASDAQ:OCS

$18.95 -0.21 (-1.07%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$10.07 -0.08 (-0.74%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$10.06 -0.02 (-0.20%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.